The Lens Journal
A journal of perspectives for young researchers

Utilization of Liposomal Nanotechnology for Targeted DNA Demethylation to Restore Normal Functioning of Cancer Cells Caused by Silenced TSGs

Diya Shah

Abstract

Recent advancements in nanotechnology have significantly improved cancer therapy by enabling the targeted delivery of therapeutic agents directly to cancerous tissues, thereby reducing systemic toxicity. Among these advancements, liposomes—lipid-based vesicles—have shown promise as versatile platforms for delivering enzymes and cofactors necessary for DNA demethylation. This critical process reverses oncogenic characteristics in cancer cells by reactivating silenced tumor suppressor genes. This paper investigates the application of liposomal nanotechnology in DNA demethylation therapies, focusing on their role in enhancing drug delivery precision and therapeutic efficacy. Surface modifications with targeting ligands improve liposomal specificity, while design advancements enhance stability and functionality within complex biological environments. Additionally, liposomes offer unique advantages such as triggered release mechanisms that respond to tumor microenvironment cues and the co-delivery of multiple agents for synergistic effects. By highlighting these capabilities, this research contributes to the development of tailored cancer therapies aimed at improving treatment outcomes and minimizing adverse effects.

Keywords: Cancer, Liposomes, Demethylation, Tumor Suppressor Genes, Targeted Therapy

I. Introduction

Cancer, a complex and pervasive disease, presents a significant global health challenge due to its multifaceted nature and varied mechanisms of progression. Among these mechanisms, the epigenetic silencing of tumor suppressor genes (TSGs) through DNA methylation has emerged as a critical contributor to cancer development. DNA methylation involves the addition of methyl groups to cytosine residues in CpG islands, leading to gene silencing and facilitating uncontrolled cell growth. Hypermethylation, characterized by the excessive addition of methyl groups to DNA, is particularly significant as it can silence TSGs, disrupting their normal function and contributing to the initiation and progression of various cancers[1]. This paper explores the potential of DNA demethylation as a therapeutic strategy to restore normal gene function by reversing these epigenetic modifications. By utilizing liposomes for targeted delivery of demethylating agents, this approach aims to enhance specificity and reduce systemic toxicity, offering a novel pathway for cancer treatment.

Tumor suppressor genes (TSGs), such as TP53 and RB1, act as guardians against cancer by regulating cell growth, promoting apoptosis, and maintaining genome stability[2]. However, their functions can be compromised when silenced

through DNA methylation, particularly in promoter regions, thereby impairing their ability to suppress tumor formation[3]. This silencing mechanism underscores the significance of TSGs in cancer biology, with over 1,000 identified genes categorized into gatekeepers, caretakers, and landscapers based on their roles in cell cycle regulation, DNA repair, and environmental interactions.

While TSG silencing is pivotal in cancer development, it interacts with genetic mutations, oncogene activation, and environmental factors to drive tumorigenesis. Specific cancers often correlate with the silencing of particular TSGs; for example, APC and MLH1 in colorectal cancer[4], BRCA1/BRCA2 and p16 in breast cancer, and p16 and RASSF1A in lung cancer. These examples highlight how epigenetic modifications contribute to diverse cancer types.

Targeted therapies represent a critical advancement in cancer treatment, focusing on precise molecular targets crucial for cancer cell survival. Unlike conventional chemotherapy, which affects healthy cells indiscriminately, targeted therapies utilize chemical tags like monoclonal antibodies and small molecule inhibitors to selectively disrupt cancer-specific molecules or pathways[5]. This approach minimizes collateral damage while enhancing treatment efficacy tailored to the molecular profile of each patient's cancer.

Demethylation processes play a pivotal role in restoring the function of silenced TSGs. Initiated by TET enzymes (TET1, TET2, and TET3), demethylation involves oxidizing 5-methylcytosine (5mC) to initiate the removal of methyl groups. The subsequent base excision repair (BER) pathway, mediated by enzymes like TDG and APE1, further repairs DNA damage caused by methylcytosine oxidation[6]. Key chemicals such as iron, alpha-ketoglutarate, and ascorbate support these enzymatic activities, ensuring efficient demethylation and restoration of normal gene function. Buffer systems and essential cofactors maintain optimal conditions for enzyme activity, underscoring the intricate regulatory processes involved.

Certain animals, like elephants and naked mole rats, exhibit natural resistance to cancer through unique biological adaptations. Elephants, with multiple copies of the p53 gene, demonstrate enhanced tumor suppression capabilities by effectively detecting and eliminating mutated cells[7]. Similarly, naked mole rats' abundance of tumor suppressor genes and efficient DNA repair mechanisms confer exceptional cancer resistance and longevity[8].

Implementing insights from these natural adaptations into human medicine holds promise. CRISPR-Cas9 technology offers precise tools for editing genes implicated in cancer progression, potentially enhancing tumor suppressor gene function or correcting genetic abnormalities[9]. This approach could revolutionize cancer therapy by harnessing natural defenses against cancer observed in resilient animal species.

Understanding and manipulating the epigenetic mechanisms involved in TSG silencing and demethylation pave the way for innovative cancer therapies tailored to individual genetic profiles. By highlighting these processes, researchers aim to enhance treatment efficacy, minimize side effects, and ultimately improve patient outcomes in the fight against cancer.

II. Literature Review

Multiple studies have explored the potential of DNA demethylation as a therapeutic strategy in cancer treatment. A study titled "DNA demethylation and invasive cancer: implications for therapeutics" highlights the complexity of targeting DNA methylation machinery, emphasizing the need to isolate the tumorigenic functions of DNMT1 from those involved in metastasis[10]. This study points out that current DNA methylation inhibitors, while capable of reactivating tumor

suppressor genes (TSGs), might also activate pro-metastatic genes, increasing the risk of metastasis. This dual effect poses a critical challenge in designing specific inhibitors that can achieve tumor suppression without promoting metastasis.

Another study, "Epigenetic modification of gene expression in cancer cells by terahertz demethylation," investigates the use of Terahertz (THz) radiation as a novel approach to DNA demethylation[11]. This research demonstrates that THz radiation can demethylate melanoma cells, resulting in altered gene expression without significant adverse effects. The study found that THz radiation downregulates genes involved in cancer and apoptosis pathways, suggesting its potential as a non-invasive method for modifying gene expression in cancer treatment. However, further research is needed to fully understand the mechanisms and long-term effects of THz radiation on DNA methylation.

In addition to these approaches, DNA methylation inhibitors such as 5-azacytidine (Vidaza) and 5-aza-2′-deoxycytidine have been approved for cancer therapy[12]. These inhibitors have shown promise in demethylating DNA and reactivating silenced TSGs. However, their potential to activate pro-metastatic genes poses a significant risk, highlighting the need to develop strategies that target TSGs while preventing the activation of prometastatic genes. This ongoing challenge underscores the complexity of using DNA demethylation as a therapeutic strategy.

The field of liposomal drug delivery has also seen significant advancements, with multiple studies[13, 14, 15] highlighting their advantages over traditional drug delivery systems. Liposomes offer targeted delivery, protection of drugs from degradation, and controlled release, making them a versatile option for cancer therapy. Several FDA and EMA-approved liposomal products have demonstrated clinical viability, leveraging advanced pharmaceutical technologies to ensure consistent quality and efficacy[13]. However, challenges remain in ensuring stability, avoiding premature drug release, and achieving efficient tumor penetration.

To address these limitations, research has focused on enhancing liposomal design and functionality. One study, "Liposomes for Tumor Targeted Therapy: A Review."[14] reviews the development of long-circulating PEGylated liposomes, which prolong circulation time and improve bioavailability. Another study[15] discusses ligand-functionalized and stimuli-responsive liposomes, which enhance targeting efficiency and ensure controlled release in response to specific environmental cues. Advanced cell membrane-coated biomimetic nanocarriers have also been explored for their improved biocompatibility and targeting capabilities. These innovations aim to tailor liposomal drug delivery systems to meet the specific needs of different cancer types and patient conditions, enhancing therapeutic outcomes.

III. Methods

This research employed a comprehensive review methodology to investigate the role of demethylation in restoring the normal functioning of cancer cells affected by silenced tumor suppressor genes and to propose solutions to overcome the limitations of existing demethylation therapies. The methodology was structured into distinct stages: data collection, selection criteria, and analysis.

3.1 Data Collection

Systematic searches were conducted across electronic databases, including PubMed, Google Scholar, and academic journals specializing in cancer research and molecular biology. The searches were performed over a six-month period from January to June 2023. Keywords used included “demethylation,” “cancer cells,” “tumor suppressor genes,” “liposomes,” “targeted therapy,” and their variations.

3.2 Selection Criteria

Studies were selected based on their alignment with the research objective of overcoming the limitations of existing demethylation therapies. The inclusion criteria emphasized recent publications (within the last ten years), comprehensive coverage of demethylation mechanisms, and insights into targeted therapies involving tumor suppressor genes. Studies were included if they provided significant insights into the effectiveness, challenges, and advancements in the field of DNA demethylation and liposomal drug delivery.

3.3 Analysis

The selected studies were synthesized and analyzed to extract key findings and trends. The analysis focused on evaluating the potential of demethylation as a therapeutic strategy, the effectiveness of liposomal delivery systems, and the challenges associated with current approaches. The findings were organized to highlight the most promising strategies and identify gaps in the current research that need further exploration.

This structured approach ensured a thorough review of existing literature and provided a solid foundation for proposing innovative solutions to enhance the specificity and efficacy of demethylation therapies in cancer treatment.

IV. Results

The literature on the use of liposomes for targeted drug delivery revealed multiple types of liposomes, each with distinct advantages and challenges[13]. The following table summarizes these findings:

Type of Liposome	Advantages	Disadvantages
PEGylated Liposomes	Enhances stability and prolongs circulation time, improving delivery efficiency.	May reduce interaction with target cells due to PEGylation.
Stealth Liposomes	Evades recognition by the immune system, prolonging circulation and enhancing bioavailability.	Requires precise engineering to maintain stealth properties.
pH-Sensitive Liposomes	Releases contents in response to tumor microenvironment acidity, enhancing targeted delivery.	Complexity in designing pH-sensitive formulations.
Cationic Liposomes	Facilitates interaction with cell membranes, improving cellular uptake.	Potential cytotoxicity and non-specific interactions.
Polymer-Stabilized Liposomes	Improved stability against fusion and aggregation, suitable for systemic applications.	Complex synthesis and potential immunogenicity.
Nanoparticle-Stabilized Liposomes	Enhances stability and allows for targeted drug delivery to specific cells or tissues.	Challenges in controlling nanoparticle stability on liposome surface.
Core-Shell Lipid-Polymer Hybrid Nanoparticles	Combines benefits of liposomes and polymeric nanoparticles, allowing multifunctional design.	Issues with batch-to-batch consistency.

Type of Liposome	Advantages	Disadvantages
Natural Membrane-Derived Vesicles	Biomimetic properties resembling natural cell membranes, facilitating specific targeting.	Difficulties in scaling up production.
Natural Membrane-Coated Nanoparticles	Enhanced biocompatibility and mimics natural cell membranes for improved targeting.	Complex preparation methods and regulatory hurdles.

4.1 Key Findings and Most Promising Liposomal Designs:

PEGylated Liposomes

- Advantages: PEGylation significantly enhances the stability and circulation time of liposomes, improving the overall efficiency of drug delivery. This makes them highly suitable for systemic therapies where prolonged drug circulation is required.
- Disadvantages: The PEGylation process may reduce the interaction of liposomes with target cells, potentially limiting their effectiveness in highly specific targeting applications.

Stealth Liposomes

- Advantages: By evading the immune system, stealth liposomes prolong circulation time and enhance bioavailability. This makes them ideal for delivering drugs that require extended presence in the bloodstream.
- Disadvantages: Maintaining stealth properties requires precise engineering, which can complicate the production process.

pH-Sensitive Liposomes

- Advantages: These liposomes can release their contents in response to the acidic environment of tumors, enhancing targeted delivery and reducing off-target effects.
- Disadvantages: Designing stable and effective pH-sensitive formulations can be complex and challenging.

Cationic Liposomes

- Advantages: The positive charge of cationic liposomes facilitates interaction with negatively charged cell membranes, improving cellular uptake.
- Disadvantages: They carry a risk of cytotoxicity and non-specific interactions, which can limit their therapeutic application.

Polymer-Stabilized Liposomes

- Advantages: These liposomes offer improved stability against fusion and aggregation, making them suitable for systemic applications.
- Disadvantages: Their complex synthesis and potential immunogenicity pose significant challenges.

Nanoparticle-Stabilized Liposomes

- Advantages: The integration of nanoparticles enhances stability and allows for targeted drug delivery to specific cells or tissues.

- Disadvantages: Controlling nanoparticle stability on the liposome surface remains challenging, affecting consistency and reliability.

Core-Shell Lipid-Polymer Hybrid Nanoparticles

- Advantages: These combine the benefits of liposomes and polymeric nanoparticles, allowing for multifunctional designs that can address multiple therapeutic needs simultaneously.
- Disadvantages: Consistency between production batches can be an issue, affecting the reliability of these liposomes.

Natural Membrane-Derived Vesicles and Coated Nanoparticles

- Advantages: These exhibit biomimetic properties and enhanced biocompatibility, improving targeting efficiency and reducing immunogenicity.
- Disadvantages: Their complex preparation methods and regulatory hurdles can be significant obstacles to their widespread adoption.

4.2 Unique Characteristics of Liposomes in Cancer Therapy

Liposomes offer unique advantages in cancer therapy[14], including:

Triggered Release Mechanisms: Liposomes can be designed to release their payload in response to specific triggers in the tumor microenvironment, such as pH changes, enzymes, or temperature.

Reducing Drug Toxicity: Encapsulation of drugs in liposomes can reduce the toxicity of chemotherapeutic agents to healthy tissues. By targeting delivery to cancer cells, liposomes help minimize side effects commonly associated with chemotherapy, such as damage to the gastrointestinal tract and bone marrow.

Co-delivery of Multiple Agents: Liposomes can co-encapsulate multiple therapeutic agents, allowing for the simultaneous delivery of drugs that may work synergistically. For example, a liposome can be loaded with both a chemotherapeutic agent and a gene-silencing RNA molecule to simultaneously attack cancer cells from different angles.

4.3 Surface Modifications with Targeting Ligands:

Additionally, surface modifications with targeting ligands further enhance liposomal specificity and effectiveness in cancer treatment[15]:

Antibodies: Conjugation of monoclonal antibodies specific to tumor antigens (e.g., HER2) enhances targeted delivery to cancer cells.

Peptides: Small peptides like RGD bind to tumor-specific receptors, improving liposomal affinity for cancerous tissues.

Aptamers: Single-stranded DNA or RNA molecules can target specific proteins on tumor cells, ensuring precise drug delivery.

By highlighting these findings, the results underscore the potential of advanced liposomal designs in improving targeted cancer therapies, particularly in the realm of DNA demethylation. The ongoing research and development in this field

aims to enhance treatment outcomes while minimizing adverse effects, paving the way for more effective and personalized cancer treatments.

V. Discussion

To address DNA methylation in cancer cells, the proposed method leverages targeted therapy with tailored chemical tags specific to each tumor type. This approach involves modifying the surface of cancer cells with chemical tags that vary according to the tumor's characteristics, ensuring precise targeting and effectiveness. While liposomes have traditionally been used for drug delivery, this method proposes expanding their application to deliver components for demethylation to hypermethylated cancer cells.

5.1 Process and Synthesis of Liposomes:

The process begins with the synthesis of liposomes, spherical vesicles composed of lipid bilayers[16], using synthetic production methods that allow precise control over their characteristics. Liposomes can encapsulate a wide range of chemicals, both hydrophilic and hydrophobic, and are versatile in targeting specific tissues or cells, including cancerous ones, without triggering significant immune responses. They are ideal for delivering the enzymes, cofactors, and buffers required for demethylation. Each component—enzymes like TET enzymes, TDG, and cofactors such as α-KG and Fe2+—is encapsulated separately in distinct liposomes to prevent interactions that could compromise therapeutic efficacy. Liposomes ensure the stability and functionality of these components during circulation, overcoming issues such as enzymatic degradation, toxicity, or pH sensitivity encountered with other delivery systems.

5.2 Customized Liposomal Designs:

The characteristics of liposomes must be customized based on the patient's physiological condition and the targeted tumor's type, location, size, and stage. While this paper does not cover all specific tumors and the corresponding types of liposomes to use, a few examples of tailored liposomal designs include:

HER2-Targeted Liposomes: Liposomes decorated with trastuzumab (Herceptin) for targeted delivery to HER2-positive breast cancer cells.

RGD-Modified Liposomes: Liposomes functionalized with RGD peptides for targeting integrins on tumor vasculature and cancer cells.

Folate-Conjugated Liposomes: Liposomes modified with folic acid for targeting folate receptors on ovarian, lung, and breast cancer cells.

Thermosensitive Liposomes: Liposomes designed to release their contents upon application of localized hyperthermia in solid tumors.

5.3 Mechanism of Action

The synthesized liposomes are employed to deliver demethylation components through targeted therapy, using chemical tags added to the tumors to guide the liposomes precisely to their target. After targeted delivery and enzymatic removal of the methyl group (CH3) from DNA—a critical process for reversing cancerous characteristics—the tumor-suppressor genes (TSGs) are unsilenced. This restoration of normal gene function is crucial for potentially reverting cancer cells to a non-cancerous state and halting tumor progression. Once tumor growth is stopped, the remaining mass of cells can either be surgically removed or left to undergo apoptosis through natural genetic processes.

5.4 Advantages Over Conventional Methods:

Unlike conventional methods using bacteria or viruses, which face technical challenges in stability and delivery, liposomes offer a superior alternative. Liposomes bypass immune detection more effectively and can be designed to respond to environmental cues such as pH or temperature changes within tumor microenvironments. This adaptability underscores their potential in personalized medicine, where each patient's treatment can be tailored based on the specificity of the tumor.

5.5 Limitations and Future Research Directions:

Despite the advantages, the proposed approach also has limitations. Designing and producing specific liposomal formulations tailored to individual patient conditions and tumor characteristics can be complex. Additionally, the long-term stability and potential immunogenicity of liposomal formulations need thorough evaluation in preclinical and clinical studies.

Future research should focus on conducting comprehensive preclinical studies to evaluate the efficacy and safety of various liposomal formulations in delivering demethylation components. Clinical trials are necessary to validate the proposed approach in diverse cancer types and patient populations. Exploring combination therapies, where liposomal demethylation agents are used alongside other targeted therapies or immunotherapies, could enhance therapeutic outcomes and provide a more robust approach to cancer treatment.

By addressing these challenges and advancing our understanding of liposomal nanotechnology, we can drive the development of innovative and effective cancer therapies that improve treatment outcomes while minimizing adverse effects.

VI. Conclusion

The utilization of liposomal nanotechnology for targeted cancer therapy through DNA demethylation represents a promising frontier in oncological treatment. By focusing on the restoration of tumor suppressor genes via epigenetic modifications, liposomes offer a nuanced approach to reversing oncogenic cellular characteristics. This method not only targets cancer cells with precision but also mitigates the systemic toxicity associated with traditional chemotherapy and radiation therapies. This is particularly advantageous for elderly patients and those unable to tolerate aggressive treatments, providing a pathway to restore normal cellular function rather than inducing cell death.

The main findings of this study highlight the versatility and effectiveness of liposomes in delivering demethylation components to specific cancer cells. Tailored liposomal designs, such as HER2-targeted, RGD-modified, folate-conjugated, and thermosensitive liposomes, demonstrate the potential to enhance treatment specificity and efficacy. These advanced liposomal formulations address the challenges of stability, targeting accuracy, and controlled release, making them highly suitable for personalized cancer therapy.

The proposed approach reduces treatment-related side effects and offers a targeted, non-toxic alternative to conventional therapies, holding significant promise for improving patient outcomes and quality of life. The potential impact of this method on cancer therapy is substantial, offering a more effective and personalized treatment option.

However, the practical application of these theoretical advancements necessitates further investigation and clinical validation. The current limitations, including the lack of primary research and extensive clinical trials, underscore the

preliminary nature of this approach. Future studies should focus on comprehensive preclinical studies, followed by clinical trials on animals and humans, to gather firsthand practical data and validate the proposed method.

Continued research and development are essential to refine these methodologies and address existing challenges. By advancing our understanding and application of liposomal nanotechnology, we can drive the development of innovative and effective cancer therapies, ultimately leading to more personalized and successful treatment outcomes in the fight against cancer.

References

1. Ehrlich M. DNA hypermethylation in disease: mechanisms and clinical relevance. Epigenetics. 2019;14(12):1141-1163. doi:https://doi.org/10.1080/15592294.2019.1638701

2. Tumor Suppressor Genes: Your protective cancer shield. Cleveland Clinic. https://my.clevelandclinic.org/health/body/24833-tumor-suppressor-genes

3. Newell-Price J, Clark AJ, King P. DNA methylation and silencing of gene expression. Trends in endocrinology and metabolism: TEM. 2000;11(4):142-148. doi:https://doi.org/10.1016/s1043-2760(00)00248-4

4. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences. 1998;95(12):6870-6875. doi:https://doi.org/10.1073/pnas.95.12.6870

5. American Cancer Society. Targeted Cancer Therapy | Targeted Drug Therapy for Cancer. www.cancer.org. Published January 29, 2021. https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/what-is.html

6. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502(7472):472-479. doi:https://doi.org/10.1038/nature12750

7. Nuwer R. Why Elephants Don't Get Cancer. Scientific American. Accessed July 12, 2024. https://www.scientificamerican.com/article/why-elephants-don-rsquo-t-get-cancer/#:~:text=Scientists%20call%20it%20Peto

8. Xia P, Xu XY. Use of tumor suppressor genes of naked mole rats for human cancer treatment. American journal of translational research. 2023;15(8):5356-5363. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492090/#:~:text=Notably%2C%20the%20naked%20mole%20rat

9. Stefanoudakis D, Kathuria-Prakash N, Sun AW, et al. The Potential Revolution of Cancer Treatment with CRISPR Technology. Cancers. 2023;15(6):1813. doi:https://doi.org/10.3390/cancers15061813

10. Cheishvili D, Boureau L, Szyf M. DNA demethylation and invasive cancer: implications for therapeutics. British Journal of Pharmacology. 2015;172(11):2705-2715. doi:https://doi.org/10.1111/bph.12885

11. Cheon H, Hur JK, Hwang W, Yang HJ, Son JH. Epigenetic modification of gene expression in cancer cells by terahertz demethylation. Scientific Reports. 2023;13(1):4930. doi:https://doi.org/10.1038/s41598-023-31828-w

12. Howell PM, Liu Z, Khong HT. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals. 2010;3(7):2022-2044. doi:https://doi.org/10.3390/ph3072022

13. Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022;27(4). doi:https://doi.org/10.3390/molecules27041372

14. Wang S, Chen Y, Guo J, Huang Q. Liposomes for Tumor Targeted Therapy: A Review. International Journal of Molecular Sciences. 2023;24(3):2643. doi:https://doi.org/10.3390/ijms24032643

15. Gao W, Hu CMJ, Fang RH, Zhang L. Liposome-like nanostructures for drug delivery. Journal of Materials Chemistry B. 2013;1(48):6569. doi:https://doi.org/10.1039/c3tb21238f

16. Lipid-based Nanoparticles. InProcess-LSP. Published July 4, 2024. Accessed July 12, 2024. https://www.inprocess-lsp.com/liposomes/#:~:text=Liposomes%20are%20spherical%20vesicles%20characterized

17. Padariya M, Jooste ML, Hupp T, et al. The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer. Malik H, ed. Molecular Biology and Evolution. 2022;39(7). doi:https://doi.org/10.1093/molbev/msac149

18. Elephant genes could hold the key to avoiding cancers | University of Oxford. www.ox.ac.uk. https://www.ox.ac.uk/news/2022-07-15-elephant-genes-could-hold-key-avoiding-cancers#:~:text=Scientists%20link%20elephants

19. Nuwer R. Why Elephants Don't Get Cancer. Scientific American. Published online October 2022. doi:https://doi.org/10.1038/scientificamerican1022-22b

20. Ingvadóttir FS. Unlocking Longevity: Cancer-Resistant Bowhead Whales Offer Clues to Human Lifespan! Arctic Portal. Published June 15, 2023. https://arcticportal.org/ap-library/news/3239-cancer#:~:text=A%20recent%20study%20reveals%20that

21. Network TL. Whales and Cancer: A Deep Dive Into Cetacean Genes. The New York Times. https://www.nytimes.com/2023/04/11/learning/whales-and-cancer-a-deep-dive-into-cetacean-genes.html#:~:text=The%20answer%20lies%20in%20that. Published April 11, 2023.

22. How many copies of tp53 (p53) gene do we have? Biology Stack Exchange. Accessed July 12, 2024. https://biology.stackexchange.com/questions/73432/how-many-copies-of-tp53-p53-gene-do-we-have#:~:text=Humans%20have%20one%20copy%20of

23. Sun Q, Uddin MdN, Li M, Wang X, Lai M. Computational Identification of Tumor Suppressor Genes Based on Gene Expression Profiles in Normal and Cancerous Gastrointestinal Tissues. Journal of Oncology. 2020;2020:2503790. doi:https://doi.org/10.1155/2020/2503790

24. American Cancer Society. Oncogenes, Tumor Suppressor Genes, and DNA Repair Genes. www.cancer.org. Published August 31, 2022. https://www.cancer.org/cancer/understanding-cancer/genes-and-cancer/oncogenes-tumor-suppressor-genes.html

25. Epigenetic Silencing of Tumor Suppressor Genes and Their Functions in Cancer Development | Frontiers Research Topic. www.frontiersin.org. Accessed July 12, 2024. https://www.frontiersin.org/research-topics/55454/epigenetic-silencing-of-tumor-suppressor-genes-and-their-functions-in-cancer-development#:~:text=Epigenetic%20silencing%20of%20tumor%20suppressor%20genes%20(TSGs)%20is%20a%20common

26. National Cancer Institute. Targeted Therapy. National Cancer Institute. Published May 31, 2022. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies

27. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11). doi:https://doi.org/10.1021/acsnano.1c04996

28. Szyf M. The role of dna hypermethylation and demethylation in cancer and cancer therapy. Current Oncology. 2008;15(2):72-75. Accessed July 12, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365485/#:~:text=The%20commonly%20accepted%20and%20attractively

29. Demethylation - an overview | ScienceDirect Topics. www.sciencedirect.com. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/demethylation

30. Oppel F, Schürmann M, Goon P, Albers AE, Sudhoff H. Specific Targeting of Oncogenes Using CRISPR Technology. Cancer Research. 2018;78(19):5506-5512. doi:https://doi.org/10.1158/0008-5472.can-18-0571